The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Over The Period 2026–2030?
The duchenne muscular dystrophy (dmd) therapeutics market size has experienced substantial expansion in recent years. It is anticipated to increase from $16.38 billion in 2025 to $21.43 billion in 2026, at a compound annual growth rate (CAGR) of 30.8%. The historical growth of this market is attributable to the rising prevalence of duchenne muscular dystrophy, enhanced awareness among healthcare providers, the initiation of early-stage clinical trials, the growing adoption of physiotherapy and supportive care, and government incentives for rare disease treatments.
The duchenne muscular dystrophy (dmd) therapeutics market size is anticipated to experience substantial growth in the coming years. It is projected to climb to $62.13 billion by 2030, achieving a compound annual growth rate (CAGR) of 30.5%. This expansion during the forecast period is fueled by progress in gene therapy, escalating investments in precision medicine, the integration of technology for patient monitoring, the broadening of biologics manufacturing capabilities, and enhanced collaborations between pharmaceutical and biotechnology enterprises. Significant trends for this period encompass the development of personalized therapeutics, continued advancements in gene editing and gene therapy, the introduction of novel drug delivery systems, the expansion of the orphan drug market, and the adoption of patient-centric care models.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
Which Major Factors Are Driving The Expansion Of The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
The Duchenne muscular dystrophy (DMD) therapeutics market is anticipated to expand due to an increase in clinical trials. These trials are research endeavors involving human subjects, designed to assess the safety, effectiveness, and potential advantages of novel medical treatments, interventions, or pharmaceuticals. The escalation in clinical trials stems from a heightened demand for pioneering therapies addressing currently unmet medical requirements. Specifically, Duchenne muscular dystrophy (DMD) therapeutics undergo testing in these trials to ascertain their capacity to decelerate disease progression and enhance muscle function for patients. As an illustration, a report released in April 2025 by the NLM (National Library of Medicine), a US-based government agency, indicated that 27,751 interventional clinical trials commenced in 2023. Consequently, this increase in clinical trials is expected to stimulate the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market.
How Is The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Divided Into Its Major Segments?
The duchenne muscular dystrophy (dmd) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
How Are Trends Transforming The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Landscape?
Leading companies operating within the duchenne muscular dystrophy (DMD) therapeutics market are embracing novel technologies to enhance the effectiveness and accessibility of therapies for DMD patients, thereby sustaining their competitive standing. For instance, in July 2023, Bit Bio Ltd., a UK-based synthetic biology firm, introduced new disease model products aimed at advancing Duchenne muscular dystrophy (DMD) treatments. These models, identified as ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes that possess genetically engineered deletions in the gene responsible for producing dystrophin protein. Bit. Bio’s models, which are reprogrammed from induced pluripotent stem cells (iPSCs), offer a reliable and scalable source of human cells for research, addressing the challenges often linked with variability and the procurement of primary cells. The models significantly aid in the development of treatments for DMD by providing crucial insights into disease mechanisms and prospective therapies. This particular advancement has the potential to accelerate the work of researchers dedicated to finding effective treatments for DMD.
Who Are The Prominent Organizations Shaping The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Exonics Therapeutics Inc., Wave Life Sciences Ltd., MeiraGTx Holdings plc, Editas Medicine Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc, CRISPR Therapeutics AG, Akouos Inc., Audentes Therapeutics Inc., Stoke Therapeutics Inc., Astellas Pharma Inc., Translate Bio Inc., Ultragenyx Pharmaceutical Inc.
Read the full duchenne muscular dystrophy (dmd) therapeutics market report here:
Which Region Currently Holds The Largest Share Of The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
North America was the largest region in the DMD therapeutics market in 2025. The regions covered in the duchenne muscular dystrophy (dmd) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Duchenne Muscular Dystrophy (DMD) Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12916&type=smp
Browse Through More Reports Similar to the Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2026, By The Business Research Company
Duchenne Muscular Dystrophy Dmd Therapeutics Market Report 2026
Duchenne Muscular Dystrophy Market Report 2026
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report
Vitamin D Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model